Shandong Wit Dyne HealthLtd Past Earnings Performance
Past criteria checks 5/6
Shandong Wit Dyne HealthLtd has been growing earnings at an average annual rate of 27.1%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 9.5% per year. Shandong Wit Dyne HealthLtd's return on equity is 26.2%, and it has net margins of 23.7%.
Key information
27.1%
Earnings growth rate
27.2%
EPS growth rate
Pharmaceuticals Industry Growth | 10.9% |
Revenue growth rate | 9.5% |
Return on equity | 26.2% |
Net Margin | 23.7% |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Shandong Wit Dyne HealthLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 2,495 | 590 | 734 | 97 |
31 Dec 23 | 2,484 | 585 | 742 | 96 |
30 Sep 23 | 2,241 | 525 | 608 | 83 |
30 Jun 23 | 2,269 | 544 | 600 | 58 |
31 Mar 23 | 2,297 | 535 | 600 | 64 |
31 Dec 22 | 2,341 | 527 | 600 | 66 |
30 Sep 22 | 2,273 | 524 | 565 | 81 |
30 Jun 22 | 2,241 | 456 | 603 | 86 |
31 Mar 22 | 2,143 | 427 | 554 | 82 |
01 Jan 22 | 2,027 | 380 | 523 | 80 |
30 Sep 21 | 2,027 | 382 | 398 | 100 |
30 Jun 21 | 2,000 | 385 | 383 | 93 |
31 Mar 21 | 1,986 | 350 | 408 | 94 |
31 Dec 20 | 1,821 | 291 | 422 | 96 |
30 Sep 20 | 1,852 | 277 | 523 | 69 |
30 Jun 20 | 1,821 | 250 | 535 | 66 |
31 Mar 20 | 1,804 | 230 | 568 | 66 |
31 Dec 19 | 1,800 | 204 | 588 | 65 |
30 Sep 19 | 1,562 | 141 | 597 | 59 |
30 Jun 19 | 1,541 | 137 | 595 | 55 |
31 Mar 19 | 1,390 | 80 | 526 | 50 |
01 Jan 19 | 1,526 | 130 | 563 | 43 |
30 Sep 18 | 1,699 | 170 | 605 | 42 |
30 Jun 18 | 1,698 | 178 | 605 | 56 |
31 Mar 18 | 1,775 | 231 | 651 | 46 |
31 Dec 17 | 1,767 | 243 | 598 | 41 |
30 Sep 17 | 1,794 | 255 | 566 | 24 |
30 Jun 17 | 1,694 | 239 | 529 | 0 |
31 Mar 17 | 1,662 | 238 | 479 | 0 |
31 Dec 16 | 1,545 | 198 | 479 | 0 |
30 Sep 16 | 1,529 | 229 | 415 | 0 |
30 Jun 16 | 1,415 | 195 | 416 | 0 |
31 Mar 16 | 1,312 | 156 | 430 | 0 |
31 Dec 15 | 1,233 | 152 | 401 | 0 |
30 Sep 15 | 1,246 | 162 | 433 | 0 |
30 Jun 15 | 1,310 | 206 | 413 | 0 |
31 Mar 15 | 1,317 | 211 | 395 | 0 |
31 Dec 14 | 1,374 | 217 | 393 | 0 |
30 Sep 14 | 1,266 | 178 | 378 | 0 |
30 Jun 14 | 1,198 | 149 | 377 | 0 |
31 Mar 14 | 1,173 | 165 | 353 | 0 |
31 Dec 13 | 1,095 | 153 | 346 | 0 |
30 Sep 13 | 1,011 | 152 | 306 | 0 |
30 Jun 13 | 957 | 148 | 292 | 0 |
Quality Earnings: 000915 has high quality earnings.
Growing Profit Margin: 000915's current net profit margins (23.7%) are higher than last year (23.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 000915's earnings have grown significantly by 27.1% per year over the past 5 years.
Accelerating Growth: 000915's earnings growth over the past year (10.4%) is below its 5-year average (27.1% per year).
Earnings vs Industry: 000915 earnings growth over the past year (10.4%) exceeded the Pharmaceuticals industry -0.01%.
Return on Equity
High ROE: 000915's Return on Equity (26.2%) is considered high.